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ABSTRACT
In prostate cancer (PC), the androgen receptor (AR)
is a key transcription factor at all disease stages,
including the advanced stage of castrate-resistant
prostate cancer (CRPC). In the present study, we
show that GABP , an ETS factor that is up-regulated
in PC, is an AR-interacting transcription factor. Ex-
pression of GABP enables PC cell lines to acquire
some of the molecular and cellular characteristics
of CRPC tissues as well as more aggressive growth
phenotypes. GABP has a transcriptional role that
dissects the overlapping cistromes of the two most
common ETS gene fusions in PC: overlapping sig-
nificantly with ETV1 but not with ERG target genes.
GABP bound predominantly to gene promoters,
regulated the expression of one-third of AR target
genes and modulated sensitivity to AR antagonists in
hormone responsive and castrate resistant PC mod-
els. This study supports a critical role for GABP in
CRPC and reveals potential targets for therapeutic
intervention.
INTRODUCTION
E26 transformation-specific (ETS) factors are involved in
the development and growth of the normal prostate (1,2)
and are overexpressed in prostate cancer (PC) compared
to benign prostate tissue (3–8). ERG, ETV1 and ETV4
have been identified as fusion partners of the androgen-
responsive gene TMPRSS2 in up to 60%, 10% and 2%
of PC, respectively (9–13). Less common fusions include
TMPRSS2-ETV5 (1,13) and other androgen receptor (AR)
responsive 5′ partners including SLC45A3 andACSL3 (14–
16). The prognostic significance of such fusions remains un-
clear (12,17,18), although high expression levels of ETS fac-
tors in PC, their correlationwith disease stage and a number
of detailed functional studies highlight a wider importance
of ETS factors in PC aside from their involvement in gene
fusions (2,4,5,8,19–21).
A recent genome-wide study of AR-binding sites in PC
suggested a functional interplay between the AR and ETS
factors (21,22) a finding subsequently expanded to ERG
and ETV1 gene fusions in PC (23–26). The transcriptional
role of ETS factors in PC, together with or independent
from the AR, was subsequently shown to promote inva-
sion, autocrine signalling and aggressive phenotypes (24–
27), thereby implicating ETS factors in tumour progression.
The ETS-factor GABP is a subunit of GABP (also
known as nuclear respiratory factor 2 (1,2)), which is an
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obligate heterotetramer consisting of two GABP and
two GABP subunits (3–8). GABP contains an ETS
DNA-binding domain near the carboxy terminus and a
pointed domain near the N-terminus. GABP contains
four ankyrin repeats (as found in Notch and many other
proteins), which interact with the carboxy terminus of
GABP and a transcriptional activation domain near its
carboxy terminus. GABP has been shown to have impor-
tant functions in hormone responsiveness (9–13), cellular
energy metabolism (1,13), cell cycle control (14–16) and cell
signalling (12,17,18).
GABP has been found to be expressed in a variety of tis-
sues (2,4,5,8,19–21), including prostate, liver, muscle, testis
and haematopoietic cells. Whilst an increased expression of
GABP has been shown in PC-3 cells (21,22), there have, as
yet, been no studies on the role of GABP in PC.
This study determines the transcriptional and phenotypic
roles of GABP in PC and identifies a novel pathway that
regulates AR signalling, analogous to the transcriptional
impact of ETV1 gene fusions.
MATERIALS AND METHODS
Cell culture
LNCaP, c4–2b, VCaP, PC-3 and Jurkat cells were used. Bio-
logical and technical triplicates were used. When androgen-
treatment experiments were performed, cells were grown to
75–80% confluence and then transferred to media supple-
mented with charcoal-stripped serum for 48 h. Cells were
then either treated with 1 nM methyltrienolone (R1881)
or an equal volume of ethanol. Treatment with 10 M
bicalutamide was performed at 75–80% confluence, in
full media. Transfections with Amaxa and the Cell Line
Nucleofector R©Kit R were used according to the manufac-
turer’s protocols and siRNA were used at 1 M (SMART-
pool ON-TARGET plus: GABP siRNA #L-011662-00-
0005; control siRNA #D-001810-0X, Dharmacon). Stable
GABP overexpression (OE) and knockdown (KD) cells
were generated using pSicoR (Addgene) and pLVX-Tight-
Puro vectors, respectively. OE andKDofGABPwere con-
firmed by both western blotting and polymerase chain reac-
tion (PCR) (Figure 4A and Supplementary Figure S3A–B).
For growth assays, 2×104 cells/well of a 48-well plate
and the IncuCyteTM system (Essen BioScience) provided
continuous time-lapse images. An integrated confluence al-
gorithm was used as a surrogate to calculate cell number.
CytoSelectTM 96-well Cell Invasion and Migration Assay
Kits (Cell Biolabs) were used with 5×104 cells/well and 24
h incubation. Fluorescence was read at 490 nm. Confocal
images were obtained using a Nikon Spectral C1Si Confo-
cal microscope. For MTS assays, MTS reagent was added
to cells, incubated at 37◦C for 2 h and fluorescence was read
at 490 nm.
Quantitative real-time PCR
RNA was extracted using Trizol and isopropanol precip-
itation and cDNA was synthesized using High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems).
Real-time quantitative PCRs were carried out in an ABI
Prism 7900, using SYBRgreen PCR master mix (Applied
Biosystems, Warrington, UK). Reactions were carried out
in triplicate and with biological replicates using a panel of
housekeeping genes (-actin, TBP, GAPDH,UBC). Primer
sequences are shown in the table below.
-Actin f: GTTTGAGACCTTCAACACCC
r: ATGTCACGCACGATTTCCC
TBP f: GAATATAATCCCAAGCGGTTTG
r: ACTTCACATCACAGCTCCCC
GABP f: ACAGAAGCCAAACAGGAGGAGGAA
r: GCATGCGTACAGAGCAAGGTTTCA
GAPDH f: ACAGTCAGCCGCATCTTCTT
r: AATGAAGGGGTCATTGATGG
PLAU f: TACGGCTCTGAAGTCACCACCAAAAT
r: CCCCAGCTCACAATTCCAGTCAA
UBC f: ATTTGGGTCGCGGTTCTTG
r: TGCCTTGACATTCTCGATGGT
PSA f: GTTGGGAGTGCAAGGAAAAG
r: CCAGCACTCAGGAGATTGTG
SEC24C f: CCATGATGGGAAGATGAAAGAG
r: GTTCCTCCTCCACGCTTTAGG
TTF1 f: CTGGGTCCTTTAGACGTCAGG
r: ATGCACGCATGCATTAGTACG
CDC2L2 f: CGCAGTTTCTTTTGGAGTCCTG
r: TCGGAACTCACCCCTACGGG
Oligo pull-down
Double-stranded DNA oligonucleotides were designed us-
ing sequences from known genomic AR-binding sites, in-
cluding the core AR response elements and ETS-binding el-
ements (Table 1). To identify AR-binding partners we mod-
ified the method of Hata et al. (23–26) with specific adap-
tations to assess AR binding. Briefly, 5′ biotin modified
complementary sense and antisense oligos (SigmaGenosys,
UK) were annealed at a concentration of 2 g/l to gen-
erate biotin tagged, double-stranded AR-binding sites. Ten
micrograms of double-stranded oligos were bound to 300
l of prewashed streptavidin magnetic beads (Promega
Magnesphere beads, Cat# Z5481) in modified HKMG
buffer (10 mM Hepes, 100 mM KCl, 5 mM MgCl2, 10%
glycerol, 0.5% NP40, 1 mM DTT, 10 M ZnCl2, 10 pM
R1881, protease inhibitors), washed three times and resus-
pended in 50l using the same buffer. LNCaP cells grown in
isotope-labelling with amino acids in cell culture (SILAC)
heavy or light isotope media were washed with ice cold
phosphate buffered saline (PBS) and harvested on ice us-
ing a cell scraper. We used heavy and light SILAC labelled
lysates to allow quantitative assessment of protein binding
to AR target containing oligos and scrambled control se-
quences. Cell suspensions were centrifuged at 1500×G for
3 min at 4◦C, resultant cell pellets were resuspended in ice
cold modified HKMG buffer (1 ml for 5 × 106 cells), son-
icated in ice water for 5 min at full power using a Biorup-
tor (Diagenode) and insoluble debris removed by centrifu-
gation at 13 000×G for 10 min at 4◦C. Cell lysates were
pre-cleared using scrambled control double-stranded oli-
gos bound to magnetic beads (prepared as above) for 1 h
at 4◦C, before incubation with AR-target double-stranded
oligos bound to magnetic beads (Table 1) for 4–16 h at
4◦C. Bead-complexes were washed five times with modified
HKMG buffer at 4◦C, resuspended in 50 l 1× denaturing
sodium dodecyl sulphate-polyacrylamide gel electrophore-
sis (SDS PAGE) loading buffer, boiled at 100◦C for 3 min
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and separated by denaturing PAGE for western blotting
or mass spectroscopy analysis or mass spectroscopy analy-
sis (GeLC-MS). For GeLC-MS analysis scrambled control
light-SILAC and AR-sequence heavy-SILAC eluates were
loaded in equal amounts on the same lane of a polyacry-
lamide gel to allow direct ratios of AR/control binding to
be calculated.
Co-immunoprecipitation
Fiftymicroliters of protein-Amagnetic beads (Dynal, Invit-
rogen) were washed three times in 1%bovine serum albumin
(BSA) in 1 × PBS before incubation overnight with 5 g
antibody (AR N20 [SC-816X, Santa Cruz], GABP [SC-
22810, Santa Cruz], ERG [SC-353, Santa Cruz]) at 4◦Cwith
gentle agitation. Antibody–bead complexes were washed
twice in 0.2 M triethanolamine pH 8.2 and incubated with
1 ml 20 mMDMP/0.2 M triethanolamine for 30 min at RT
with gentle agitation. Cross-linking was stopped by the ad-
dition of 1 ml 50 mMTris pH 7.5 and incubation for 15 min
at RTwith gentle agitation. Antibody/bead complexes were
washed three times in 1% BSA/PBS, resuspended in 50 l
of the same buffer, combined with cell lysates and incubated
for 3 h at 4◦C with gentle agitation. Lysate/antibody/bead
complexes were washed four times with 2% lysis buffer and
analysed using western blotting.
Immunoblotting
The following antibodies were used for western blotting:
anti-GABP (Santa Cruz 28312), anti-AR (Santa Cruz
sc-816), anti-cyclin D1 (Cell Signalling 2926), anti-CDK4
(Cell Signalling 2906), p27Kip1 (Cell Signalling 3686), anti-
-actin (AbCam 2676). ECL PlusTM System (GE Health-
care) was used to visualize the signals.
Far western
Purified AR domains (NTD-DBD and LBD-DBD, gift
from I McEwan, Aberdeen) were quantified using a Brad-
ford Assay and following SDS PAGE were transferred to
a polyvinylidene fluoride membrane. Far western was per-
formed as previously described (24–27) including incuba-
tion with purified GST-GABP and a primary antibody
against GABP (Atlas, HPA003258, 1:500).
Cell cycle analysis
Double thymidine block was used as previously described
(28). For DNA content analysis, cells were trypsinized us-
ing 0.25% Trypsin-EDTA (Invitrogen), washed in PBS, re-
suspended in 80% ice cold methanol and stored at −20◦C
until staining. Methanol-fixed cells were treated with 3 M
DAPI (Sigma) overnight at 4◦C. Fluorescence activated cell
sorting (FACS) analysis was carried out using a BD LSRII
instrument (Becton&Dickinson, San Jose, CA) and data ac-
quisition was performed using BD FACSDiva software (v.
6.1.3.). The fluorescence emitted by DAPI was collected us-
ing a 450/50 bandpass filter. Data were analysed after dou-
blet discrimination (29) using the FlowJo software (Tree
Star, v. 8.8.4.).
Illumina expression arrays
RNA was extracted using Trizol and isopropanol precipi-
tation from biological triplicates. cRNA was generated and
biotin labelled using the Illumina TotalPrep RNA Ampli-
fication Kit. Hybridization and scanning were performed
using standard Illumina protocols. Expression analysis was
carried out on Illumina Human version 4 HT12 arrays and
data analysis was carried out using R (RDevelopment Core
Team, 2010) (www.r-project.org) and Bioconductor (30).
The arrays were processed with the BASH (31) and HULK
algorithms, from the beadarray package (32) to remove
spatial artefacts. Intensity data were log2 transformed and
quantile normalized. Differential expression analysis was
carried out using the limma package (33). Differentially ex-
pressed genes were selected using a P-value cut-off of<0.05
after application of false discovery rate (FDR) correction
for multiple testing applied globally to correct for multiple
contrasts. For integrative analyses and ontology enrichment
we used a significance threshold of 0.1 after adjustment for
multiple testing (as previously described (34,35)).
ChIP-seq
ChIP was performed as previously described (22,36,37) us-
ing the following antibodies: AR N20 [SC-816X, Santa
Cruz], GABP [SC-22810, Santa Cruz], ERG [SC-353,
Santa Cruz]. Biological replicates were used. Enrichment
was tested with 6 l DNA by real-time PCR using
SYBRgreen (Applied Biosystems). Single-end SOLEXA
libraries were prepared as previously described (36) and
36 bp sequence reads were generated by the Illumina
HiSeq 2000. Sequence reads were aligned against the
Human Reference Genome (assemby hg18, NCBI Build
36) using Burrows-Wheeler Aligner (BWA) version 0.5.5
(38). Reads were filtered by removing those with a BWA
alignment quality score less than 15 as well as dupli-
cate reads. Enriched regions of the genome were iden-
tified by comparing ChIP samples to input samples us-
ing MACS (39) and SWEMBL (http://www.ebi.ac.uk/∼
swilder/SWEMBL/). Only peaks that were identified by
both MACS and SWEMBL (high confidence peaks) were
used for further analyses.
Data analysis
Androgen receptor binding sites (ARBS) identified in cell
lines were compared to publicly available transcription fac-
tor ChIP data sets (data generated in the present study are
deposited under the GEO accession GSE49093 and pub-
lished data for the AR, ERG, ETV1 were obtained from
GSE28126, SRA014231 and GSE47120, respectively) (24–
26,40) by calculating the percentage overlap of BS (≥1 bp
overlap) for all pairwise comparisons between samples, cor-
related using Eisen Cluster (41) and plotted as heatmaps.
Overlap, subtraction, union, and feature annotation of
ChIP-seq enriched regions were done using the Galaxy web
site (42,43). Motif-enrichment analysis and evolutionary
conservation of the ARBS identified were performed using
Cis-regulatory Element Annotation System (CEAS) (44).
Functional annotation of the genes associated with each of
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Table 1. Sequences of AR/ETS and scrambled control oligonucleotides used for oligo pull-down experiments (shown as 5′–3′ sequences; oligos were 5′
biotin labelled)
ACATGTGGTCCACATCCGGGTTTTTAGCAGAACATAGGTAT UNQ-motif2-ETS1-S
ATACCTATGTTCTGCTAAAAACCCGGATGTGGACCACATGT UNQ-motif2-ETS1-AS
ACATGTGGTCCACActCGGGTTTTTAGCAGAACATAGGTAT UNQ-motif2-MUT-ETS1-S
ATACCTATGTTCTGCTAAAAACCCGagTGTGGACCACATGT UNQ-motif2-MUT-ETS1-AS
ACATGTGGTCCACATCCGGGTTTTTAGCgcAAaATAGGTAT UNQ-MUTmotif2-ETS1-S
ATACCTATtTTgcGCTAAAAACCCGGATGTGGACCACATGT UNQ-MUTmotif2-ETS1-AS
ACATGTGGTCCACActCGGGTTTTTAGCgcAAaATAGGTAT UNQ-MUTmotif2-MUT-ETS1-S
ATACCTATtTTgcGCTAAAAACCCGagTGTGGACCACATGT UNQ-MUTmotif2-MUT-ETS1-AS
AR and ETS core binding sequences are indicated by underlined text, scrambled bases are indicated by lower case letters. Sequences labelled ‘MUT’ denote
scrambled control sequences.
the ARBS was performed using Genomic Regions Enrich-
ment of Annotations Tool (GREAT) (45) and Gene set en-
richment analysis (GSEA) (46,47). ARBS were integrated
with gene expression data using a genomic window of 50 kb,
and these genes were used to mine publicly available expres-
sion data sets. Kaplan–Meier curves were produced using
recursive partitioning (48) on the Glinsky data set of clini-
cal outcomes in PC, with relapse defined as two successive
PSA rises greater than 0.2 ng/ml (49).
Animal experiments
2 × 106 luciferase-expressing c4–2b cells (shGABP or
scrambled control) in an equal volume of MatrigelTM (BD
Biosciences) were injected subcutaneously in NOD-SCID
gamma mice (Charles River) and mice were castrated via
bilateral scrotal incisions under general anaesthesia when
tumours reached 100mm3. Luminescencewasmeasured us-
ing Xenogen IVIS50 imaging after injection of D-luciferin
150 mg/kg (Caliper Life Sciences, 122796) and analysed
using Living Image 3.0 (Xenogen Imaging Analysis). All
animal experiments were performed in the Cambridge Re-
search Institute using approved protocols under Home Of-
fice PPL 80/2301.
Immunohistochemistry
Immunohistochemistry was performed using AR-N20
(Santa Cruz #sc-816, 1:100) and GABP (Santa Cruz #sc-
22810, 1:200) antibodies on paraffin-embedded material.
Full ethical approval was obtained for all human sample
collections from Addenbrooke’s Hospital Research Ethics
Committee (MREC 01/4/061). Custom-made tissue mi-
croarrays (TMAs) were used, containing either samples
from 104 patients with PC who underwent radical prosta-
tectomy (at least two distinct regions of cancer from each
patient and matched cores from benign regions) or sam-
ples from patients with castrate-resistant prostate cancer
(CRPC).
Two scientists (H.E.S. and A.Y.W.), one of whom is a
Consultant Histopathologist (A.Y.W.), performed the scor-
ing independently and with no knowledge of the patients’
clinical status. Staining intensity for GABP was evaluated
as the percentage of nuclei stained and also on a four-point
scale: 0 (negative), 1 (weak), 2 (moderate) and 3 (strong).
The resultant H-score incorporates both pieces of data (H-
score= intensity×%positive stained cells). Statistical anal-
ysis was performed using the Chi-square test.
We define biochemical recurrence (BCR) as a single
prostate-specific antigen value of >0.2 ng/ml with per-
sistent elevation on subsequent prostate-specific antigen
measurements or ‘triggered treatment’ (e.g. radiotherapy,
Luteinizing hormone-releasing hormone (LHRH) ana-
logue). Time to recurrence was defined as time from radical
prostatectomy to recurrence. To compare the difference in
H-score between tumour and matched normal/benign, the
Wilcoxon matched-pairs signed-rank test was performed.
To assess the effect of GABP expression on PC patient
outcome, patients were divided into groups based on quar-
tiles of their GABP H-score (using the method of Hyn-
dman and Fan (p[k] = ∼ median[F(x[k])])). Data were fit-
ted using a Cox proportional hazards regressionmodel with
samples grouped based on GABPH-score into first quar-
tile and quartiles 2–4 (using the ‘survival’ package in the
R statistical software). Kaplan–Meier plots were generated
with 95% confidence intervals shown to illustrate the pro-
portion of patients free of BCR after radical prostatectomy,
censoring at the last date of follow-up. A Cox proportional
hazards model was used to evaluate the association between
GABP staining and time to relapse, accounting for grade,
stage, surgical margins, age and PSA at diagnosis. Clinical
and pathological information was compared with GABP
staining using either a Mann–Whitney test for continuous
data or Fisher’s exact test for categorical data,P< 0.05 con-
sidered to be significant.
RESULTS
GABP is a clinically relevant ETS-family member and in-
teracts with the AR
We used an unbiased in vitro oligo pull-down method cou-
pled with SILAC and mass spectrometry (MS) detection
to identify potential AR co-factors in LNCaP PC cells
(23) (Figure 1A–C). Several knownAR-interacting proteins
were among the most enriched proteins identified, validat-
ing the method (2) (e.g. CALR, RELA and SPDEF; Sup-
plementary Figure S1B and Supplementary Table S1). Us-
ing this approach GABP was identified as the ETS factor
showing the highest selective binding to oligonucleotides
containing an endogenous AR-ETS sequence (from the
UNQ9419 promoter) (22), despite the higher expression of
other ETS factors belonging to the same functional class
(50) (Figure 1D–E and Supplementary Figure S1). GABP
showed the highest enrichment on wild type versus scram-
bled AR-ETS oligonucleotide pull-down (Figure 1D–E, se-
quences of oligonucleotides in Supplementary Figure S1A)
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Figure 1. GABP is a clinically relevant AR-interacting partner. (A) Schematic showing the steps involved in the oligo pull-down method used to identify
proteins which bind to AR-DNA target complexes. (B) Overview of the experimental design of oligo pull-down SILAC quantitative mass spectroscopy
experiments. (C) Summary plot of SILACMS results from oligo pull-down material using wild type (WT) and scrambled (mut) dsDNA oligos incubated
with heavy or light isotope labelled LNCaP cell extracts, respectively. Oligo sequences contained. (D) Bar chart of SILAC MS heavy/light ratio of the
AR, GABP and GABP binding to AR-ETS containing oligos and scrambled control sequences. (E) Western blot validation of MS results showing AR,
GABP and GABP binding to WT but not scrambled control sequences. Different buffers were used in the preparation of samples for oligo pull-down
(HKMG) and IP/input (RIPA) which may have altered migration of GABP and GABP or the preservation of PTMs. (F) Kaplan–Meier recurrence-free
survival curves showing significant predictive ability of ETS-factors GABP and ETV1 in a clinical expression data set of PC using recursive partitioning
(Glinsky et al. (49)). (G) GABP and AR western blot of co-immunoprecipitation using GABP, AR (N20) and control IgG antibodies in LNCaP cells,
molecular masses (kDa) shown. (H) Representative images of GABP immunostaining in benign prostate tissue, Gleason score 6 PC and Gleason score
10 CRPC, ×20 magnification. (I) Immunohistochemistry of human PC samples on a 104-patient TMA scored according to GABP nuclear staining and
intensity (negative to high). Percentages of sample totals are shown for benign versus varying Gleason grades of PC. * and ** P< 0.05, Chi-square test. (J)
Kaplan–Meier survival curve indicating time to biochemical recurrence for patients with no/low GABP staining (H-score ≤98) or high GABP staining
(H-score 98–300), using the Cox proportional-hazards regression model. AR, androgen receptor; PC, prostate cancer.
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and also in orthologous experiments comparing AR-ETS
oligo pull-down in LNCaP cells with AR KD versus RNAi
control (Supplementary Figure S1B). Validation oligo pull-
down experiments using control sequences which lacked ei-
ther AR half-sites or ETS motifs confirmed GABP bind-
ing at this AR target site, although for this in vitro assay
ETS sites did not appear to affect AR binding to half-sites
(Figure 1E and Supplementary Figure S1B), suggesting that
GABP is unlikely to have any pioneer factor activity for
the AR. However, several AR cooperating transcription
factors have been shown to regulate AR signalling by con-
verging on common sets of target genes without evidence
of cooperative binding (e.g. OCT1-AR (51)), therefore we
did not use cooperative binding as a criteria to include or
exclude candidates for further study.
The expression of all ETS factors was analysed in a pub-
licly available clinical expression data set of clinical PC sam-
ples with accompanying survival data (49) using recursive
partitioning. High expression of GABP was significantly
correlated with lower rates of recurrence-free survival (P <
0.05, Figure 1F), providing evidence of clinical relevance
to support our unbiased proteomics-based identification of
GABP as a potential candidate for modulating AR func-
tion.
An interaction between the AR and GABP was con-
firmed in vitro (Figure 1G and Supplementary Figure
S1C-E). Immunostaining was performed on custom-made
TMAs of PC and examples of GABP immunostaining are
shown in Figure 1H. In a TMA containing matched be-
nign and PC samples from patients who underwent radical
prostatectomy (median follow-up time 91 months, range 3–
151), we foundGABP expression to be significantly higher
in tumours (median H-score 153) compared with matched
benign samples (median H-score 0) and in more aggres-
sive, D’Amico high-risk Gleason score 8–10 PC (52) com-
pared to Gleason score 6 PC (P < 0.05, Figure 1H–I, Sup-
plementary Table S2). In addition, GABP expression was
maintained in CRPC and higher than in benign prostate
tissue (Figure 1H). In evaluating the association between
GABP H-score and BCR, we divided patients into two
groups based on low versus medium–high GABP staining
(taking the first quartile as the cut point which showed the
most significant difference). There was a significantly higher
risk of BCR for patients with high GABP staining (H-
score >98, second through fourth quartile) compared with
those with no or low GABP staining (H-score ≤98), P =
0.025 (Figure 1J). However, these correlations with GABP
expression will require validation in larger cohorts.
GABP directs a distinct transcriptional programme in PC
Previous studies have shown significant overlap in ETS-
factor-binding sites, including a short common core-ETS-
binding site (GGAA/GGAT), and such widespread redun-
dancy in promoter occupancy by ETS factors has been
implicated in tumourigenesis (53). Transcriptional activi-
ties of ETS factors have been well described in haemato-
logical cancers using Jurkat cells (53,54), and ERG tran-
scription has been studied in PC using VCaP cells (24).
Therefore, Jurkat and VCaP cells (treated either with syn-
thetic androgen or ethanol) were used forGABP andERG
ChIP-seq in order to determine if our findings were spe-
cific to PC cells, GABP or were common features of other
ETS-familymembers. Peaks were identified using two peak-
calling algorithms and only those identified in both (high
confidence peaks) were taken forward for further analy-
sis (details in Materials and Methods section, summary in
Supplementary Table S3). Known binding targets were val-
idated by ChIP-PCR (Figure 2A) and binding sites identi-
fied by ChIP-seq were highly conserved and correlated well
with previous studies (Figure 2B-C, Supplementary Table
S4 and Supplementary Figure S2).
As has previously been shown for other ETS factors
(53,54), there were many common binding sites for GABP
and ERG in Jurkat cells, although far less redundant pro-
moter occupancy was identified in VCaPs (28.5 and 9.0%
overlap, respectively, Supplementary Table S4). Surpris-
ingly, we also found a small but significant set of directly
overlapping binding sites for GABP and the AR in VCaP
cells (9–16% overlap, P < 0.05, including the endogenous
site used in the initial oligo pull-down; Figure 2C and Sup-
plementary Table S4), although there was significant over-
lap in the genes adjacent to GABP (<10 kb) and AR (<25
kb) binding sites identified in cell lines and tissue (32 and
35%, respectively for peaks <10 kb or <25 kb from genes,
hypergeometric P < 0.01; Figure 2D and Supplementary
Table S5). These data suggest that although GABP and
the AR can bind to the same regulatory elements the more
common association is by converging on shared sets of gene
targets. To further explore these unexpected results we ex-
tended our analysis to include data sets from previous stud-
ies that mapped ERG- and ETV1-binding sites in PC cells
(24,25), since these ETS fusion genes have also been impli-
cated in modulating AR signalling (24,25). Detailed analy-
sis revealed that GABP-binding sites directly overlap with
those of ETV1 (n = 5293 peaks, 88%, hypergeometric P
< 0.001 (55–58), Genomic HyperBrowser proximity test P
< 0.005 (59–62)) but not ERG (n = 202 peaks, 3%, hy-
pergeometric P > 0.05, Genomic HyperBrowser proximity
test P > 0.05) in PC cells (Figure 2C and Supplementary
Figure S2B-H). Given the convergence of both ERG with
the AR and ETV1 with the AR, these results were unex-
pected but were supported by further analysis of genomic
occupancy (Supplementary Figure S2C-E), motif enrich-
ment (Figure 2E) and functional enrichment (Figure 2F),
all of which pointed towards two distinct sets of targets
occupied by ERG or GABP and ETV1. Specifically: (1)
ERG binding was mainly distant from genes (50–500kb),
GABP binding was enriched at gene promoters (<5 kb)
and ETV1 binding showed a wide distribution encompass-
ing both profiles (Supplementary Figure S2C-E); (2) mo-
tif analysis highlighted common features for GABP- and
ETV1-binding sites which were distinct from ERG-binding
sites (Figure 2E); (3) GABP and ETV1 target genes were
specifically enriched for metabolic, stress response, DNA
damage and MYC-like oncogenic signatures, while ERG
target genes were enriched for distinct sets of gene signa-
tures (Figure 2F). Genes associated with ERG- and ETV1-
binding sites (GREAT closest feature analysis (45)) were
significantly enriched for up-regulation in PC tissue and
androgen-regulation in vitro (Figure 2F), in contrast to
genes near GABP-binding sites which were enriched for
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Figure 2. GABP and ERG regulate distinct pathways in PC. (A) ChIP-PCR validation of known ERG (i) and GABP (ii) binding targets in Jurkat and
VCaP cells. Enrichment shown relative to input and normalized to housekeeping genes. Error bars, standard deviation. (B) Venn diagrams showing overlap
of ETV1 peaks from PC cells (Chen et al. (25)) with those for GABP and ERG in this study. Total numbers of peaks in each set are shown in parentheses
and the numbers of overlapping peaks between sets are indicated in the overlapping regions of the Venn diagrams. (C) Heatmap showing the concordance
between AR, ERG, ETV1 and GABP ChIP sets from PC and Jurkat cell lines (Chen et al. (25), Sharma et al. (66)), represented as percentage of set.
(D) Example of GABP, AR and ERG binding in cell lines and CRPC tissue at the TRMT12 locus. (E) CEAS motif enrichment analysis of GABP-,
ETV1- and ERG-binding sites identified using ChIP-seq in PC cell lines (Yu et al. (24), Chen et al. (25)). (F) GREAT (Genomic Regions Enrichment of
Annotations Tool) analysis of GABP-, ETV1- and ERG-binding sites identified in PC cell lines.
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genes up-regulated in CRPC and showed greater enrich-
ment for AR binding in CRPC tissue than AR binding in
PC cell lines (Supplementary Table S4 and Figure 3G). To-
gether these data highlight a distinct set of transcriptional
targets for GABP in PC cells that is most similar to the
profile of the commonly translocatedETV1ETS factor. The
profile of GABP binding at the promoters >30% of AR-
regulated genes was particularly interesting and prompted
further functional genomic studies.
GABP regulates the transcriptional activity of the AR
A panel of cell lines was generated with KD or OE of
GABP in PC cells representing well-characterized models
of androgen-dependent (AD) and castrate-resistant (CR)
metastatic PC (Figure 4A and Supplementary Figure S3A-
B) for use in transcriptional and functional studies.
To define a core set of GABP-regulated genes we
selected genes showing both significant up-regulation in
GABP OE and down-regulation in GABP KD, iden-
tifying 1825 genes in AD (LNCaP) cells and 1655 genes
in CR (c4–2b) cells (with a 19% overlap, n = 316 genes,
Supplementary Table S6). GABP-binding sites identified
by ChIP-sequencing were enriched near this core set of
GABP-regulated genes with 29% showing GABP bind-
ing within 10kb (P < 0.05, n = 106 genes, Supplementary
Table S6). A subset of the core GABP differentially ex-
pressed genes were known AR targets from previous ChIP
studies in PC (22) (33% of, n = 1046 Figure 3A, P < 0.05)
and we also observed similar overlaps in subsets of GABP
targets (e.g. 44/106 genes, P < 0.01, were AR targets and
<10 kb from GABP-binding sites with concordant regu-
lation followingGABPKDorOE in bothLNCaP and c4–
2b cells), providing further support for an interplay between
the transcriptional activity of AR and GABP. This con-
vergence of AR and GABP targets at the gene level pro-
vides a cross-platform and cross cell line validation of the
observed enrichment of GABP and AR binding around
a core set of target genes, despite their divergent patterns
of genomic binding (Figure 2D, Supplementary Figure S2
and Supplementary Tables S5–S6). A subset of genes which
was differentially expressed by GABP PC cells and as-
sociated with AR- and GABP-binding sites were signifi-
cantly predictive of survival in PC (49), including both in
vitro androgen-regulated and not in vitro-regulated genes
(25.4%, n= 442, an example STIL shown in Figure 3G,P<
0.05), highlighting the potential importance of the interplay
between GABP and the AR. However, GABP clearly
affects other transcriptional programs in addition to the
AR in PC cells as a large proportion of GABP-regulated
genes were not androgen-regulated in PC cells (22) (Fig-
ure 3A), consistent with the low enrichment of AR targets
among GABP genomic binding sites, compared to ERG
and ETV1 (Figure 2F).
GABP regulates a distinct gene network in PC
Functional annotations (DAVID (63)) revealed that dif-
ferentially expressed genes in GABP LNCaP cells (up-
regulated in OE and down-regulated in KD, n = 1825)
were associated with the regulation of apoptosis and Rho,
mTOR and p53 signalling pathways, whereas in c4–2b cells
such differentially regulated genes (n = 1655) were associ-
ated with ribosomal biogenesis, and MAPK, STAT3, Jak-
STAT and Wnt signalling pathways (Figure 3B). Despite
the large numbers of concordantly regulated GABP tar-
gets in LNCaP and c4–2b cells (n = 374), these divergent
functional enrichments suggest some context-dependent
differences in GABP signalling which may reflect the dis-
tinction between these models of localized disease and
CRPC. However, in both cell lines there are common fea-
tures that highlight the enrichment of metabolic and stress
response signatures regulated by GABP (Figure 2F).
Further analysis revealed that 237 of the 335 previously
described ES-associated Myc-signature genes (64) were dif-
ferentially expressed inGABPOE (Figure 3C), underscor-
ing the enrichment of MYC signatures found for GABP
and also ETV1 targets (Figure 2F). A subset of these (8.9%)
were significantly predictive of poor survival in a publicly
available clinical expression data set of PC (49), an exam-
ple HNRPK (overexpressed in GABP OE) is shown in
Figure 3D. Additionally, differentially expressed genes (ei-
ther up- or down-regulated) in GABP OE PC cells (both
LNCaP and c4–2b cells, n= 3185) were able to segregate be-
nign, primary and metastatic PC clinical samples, with the
largest expression changes occurring in metastatic CRPC
samples (65) (Figure 3E), highlighting the clinical impor-
tance GABP targets in PC and CRPC. Such differentially
expressed genes in GABP OE PC cells were associated
with steroid biosynthesis, p53, Wnt, and MAPK signalling
pathways, and were up-regulated in other cancers, includ-
ing colorectal and renal cell (Figure 3F), providing further
evidence for the role of GABP in PC progression through
these key oncogenic pathways and providing further cross-
validation of the similarity with the role of ETV1 from pre-
vious studies (25,26).
OE of GABP mimics a CRPC signature
GABP-binding sites overlapped directly with over one
hundred in vivo AR-binding sites identified in CRPC tis-
sue (Supplementary Table S4 and Supplementary Table S5)
with shared targets including those from our previously de-
scribed core CRPC gene signature (e.g. STIL, TRMT12,
CEBP and TM4SF1), further highlighting the potential
clinical relevance of GABP in CRPC. These overlapping
targets showed enrichment for Rho and activin signalling
pathways and Rho GTPase activity (P = 7.4 × 10−5, 8.6 ×
10−4 and 6.3 × 10−7, respectively). GABP directly regu-
lates the expression of 9/16 core genes associated with clin-
ical CRPC (SLC26A2, SEC61A1, TRMT12, TNFSF10,
PECI, MAD1L1, STIL, TSPAN13 and AGR2, (66)), as
identified by the presence of a GABP-binding site close to
(< 25 kb) these genes and their differential expression fol-
lowing alteration in GABP levels in PC cells (Figure 3H–
I).
GABP mediates a malignant phenotype and contributes to
AR antagonist resistance in PC
A panel of cell lines were generated with KD or OE of
GABP in PC cells representing AD and CR metastatic
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Figure 3. GABP regulates distinct gene networks in androgen-dependent and androgen-independent PC. (A) Pie charts showing genes down-regulated in
GABP-KD and up-regulated in GABPOE cells, divided into those which are known AR targets in PC and those which are not, from publicly available
AR ChIP data sets (Massie et al., 2011), further sub-divided into those which are known androgen-regulated genes and those which are not, from publicly
available expression data sets (Massie et al., 2011). (B) GO biological processes and KEGG pathways enriched in genes up-regulated in GABP OE and
down-regulated in GABPKD LNCaP (n = 1825) and c4–2b (n = 1655) cells. (C) Heatmap showing profiles of Myc-signature genes (Wong et al. (64)) in
GABP cells. (D) Kaplan–Meier survival curve showing significant predictive ability for HNRPK (up-regulated in GABP OE PC cells) within a clinical
expression data set of PC (Glinsky et al. (49)). (E) Gene-expression heatmap showing segregation of metastatic samples from benign and localized PC
samples (Varambally et al.(65)) using the gene set identified in GABP OE PC cells. (F) GO biological processes and KEGG pathways enriched in genes
differentially expressed in both GABP OE PC cells and in metastatic versus localized PC, showing selected terms that passed significance. (G) Kaplan–
Meier survival curve showing significant predictive ability for STIL (up-regulated in GABP OE PC cells and associated with AR- and GABP-binding
sites) within a clinical expression data set of PC (Glinsky et al. (49)). (H) Heatmap showing expression of the core 16 AR CRPC gene set (Sharma et al.
(66)) in GABP OE and KD c4–2b and LNCaP cells. (I) ChIP-PCR validation of STIL and TRMT12 as binding sites of the AR in CRPC tissue and of
GABP in VCaP cells. Enrichment normalized to input and relative to housekeeping genes, error bars SD. AR, androgen receptor; PC, prostate cancer;
GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
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Figure 4. GABP mediates a malignant phenotype in PC. (A) Western blot analysis in GABP KD in PC-3 (lacking functional AR) and LNCaP and
c4–2b cells, respectively, and in doxycycline-inducible GABP OE in LNCaP and c4–2b cells. Invasion of (B) LNCaP, c4–2b and PC-3 cells with GABP
KD and of (C) LNCaP and c4–2b cells with GABPOE, shown as% of control cells, grown in the presence of androgen, * P< 0.01. Confluency of LNCaP
(D) and c4–2b (E) cells with GABPKD compared to control,± bicalutamide treatment. Confluency of LNCaP (F) and c4–2b (G) cells with GABPOE
compared to empty vector, ± bicalutamide treatment. (H) Subcutaneous xenograft tumour growth assay using luciferase-expressing PC cells with GABP
KD (GABP-sh) or scrambled control (NT-sh),± castration of SCIDmice. Left panel shows results from intact uncastrated xenografts (‘full’). Right panel
shows results from xenografts established in uncastrated intact (‘full’) mice, followed by castration to assess the effects of androgen withdrawal (dashed
line indicates time-point of castration). Bioluminescence was assessed using the IVISR© system and results are shown as boxplots, * P < 0.05. (I) Results
of linear regression analysis of growth rates of xenografts as in panel (H), * P < 0.05. In both plots red bars denote GABP-shRNA clones and grey bars
denote scrambled control shRNA clones. Right panel compares xenograft tumour growth rates before (pre-castr.) and after castration (post-castr.).
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PC (Figure 4A and Supplementary Figure S3A-B). GABP
KD cells containing a functional AR (but not those with-
out a functional AR, PC-3 cells) showed significantly re-
duced invasiveness, relative to control cells (13.5 ± 2.9%
and 45.8 ± 5.1% in LNCaP and c4–2b cells, respectively,
P < 0.01, Figure 4B). Significantly increased invasiveness
was seen in GABP OE cells (226.6 ± 8.1% and 206.1 ±
7.3% in LNCaP and c4–2b cells, respectively, P< 0.01, Fig-
ure 4C). Migration was similarly affected and wound heal-
ing was significantly delayed by GABP KD (Supplemen-
tary Figure S3C–D and F–G). GABP has previously been
shown to be critical for cell cycle progression (14,67) via
its gene targets E2F1, thymidylate synthase (TYMS) and
SKP2 (68–70). Synchronized PC cells were monitored by
FACS and levels ofGABPwere highest in S andG2 phases
(Supplementary Figure S4A-B). GABP KD resulted in a
small but significant reduction in the proportion of cells in
S-phase and a small but significant increase in the propor-
tion of cells in G2 phase (Supplementary Figure S4C). Al-
though cell growth was not significantly altered by KD of
GABP (MTS assay, Supplementary Figure S3E), GABP
KD in LNCaP (AD) cells in vitro leads to inhibition of con-
fluency and a synergistic effect was seen with bicalutamide
(AR antagonist) treatment (Figure 4D). GABP KD in
c4–2b (CR) cells leads to increased sensitivity to bicalu-
tamide (Figure 4E). GABP OE resulted in desensitization
of both AD and CR PC cells to bicalutamide (Figure 4F–
G). Reduced tumour growth rates of GABP KD PC cells
were observed in a pre-clinical model (flank subcutaneous
xenografts in immunodeficient mice) with tumours remain-
ing sensitive to GABP KD following surgical castration
(Figure 4H). Using a bioluminescent PC cell line we tracked
the growth of individual xenografts over time. Linear re-
gression analysis of these growth rates provided further ev-
idence for reduced xenograft growth rates in GABP KD
cells compared to controls (Figure 4I), showing a signifi-
cant difference in CRPC tumours emerging after castration
(P < 0.05, Figure 4I).
DISCUSSION
Many interacting proteins have been identified for the AR,
including several ETS factors such as ETS1 (22), ETV1
(25,26), ERG (24,71), ETV5 (72) and SPDEF (2). All do-
mains of the AR have been identified as interacting sites
for ETS factors, such as the DBD for SPDEF, the LBD for
ETV1 and the NTD and DBD-LBD domains for ETV5.
This study has identified GABP as an interacting partner
of the AR, which modulates AR signalling in PC cells by
binding to the promoters of androgen-regulated genes and
conferring a CRPC-like gene signature and cellular phe-
notype. High GABP expression in clinical material is as-
sociated with an increased risk of BCR following surgery
for PC. We identified a GABP transcriptional signature
which shows similarities with those of commonly rear-
ranged ETV1 ETS gene and impacts on central and steroid
metabolism, stress response and signalling through small
GTPases, WNT and MAPK.
The malignant phenotype mediated by GABP was ob-
served in LNCaP and c4–2b cells, but not in PC-3 cells,
which contain very low or absent levels of a functional AR
(73), suggesting that this phenotype could be AR-mediated.
However, the increased growth rate in GABP OE cells
demonstrated a growth advantage which is independent of
AR transcriptional activity, providing evidence for GABP
maintaining and promoting growth even in cells lacking a
functional AR.GABP has previously been shown to effect
migration of vascular smoothmuscle cells, possibly through
its regulation of KIS, which in turn modulates p27Kip1 (14).
OE of p27Kip1 has been shown to increase the migration
of cancer cells in vitro (74), and the levels of p27Kip1 were
increased in PC cells after GABP KD (Supplementary
Figure S4D), supporting this possible mechanism of in-
vasiveness in PC. However, we also identified several pro-
migratory gene signatures and functional enrichments in-
volving small GTPases which could also contribute to the
observed pro-migratory phenotype elicited by GABP in
AR positive PC cells.
The observed reduction in S-phase cells in GABP KD
cells is consistent with previous reports in other cell lines,
which have suggested this effect could be mediated by a
reduction in the level of SKP2 (S-phase kinase-associated
protein 2), an E3 ubiquitin ligase that controls the levels of
cyclin-dependent kinase inhibitors p21 and p27 and hence
progression of the cell through S andG2 phases (70). Signif-
icant reductions in the mRNA levels of SKP2 and TYMS
were observed inGABPKDPC cells (Supplementary Fig-
ure S4E), suggesting that this, together with the increase in
p27Kip1, could also be the mechanism by which cells with
GABP KD are delayed from entering S-phase. However,
the reduction in cells in S-phase following GABPKDwas
greater in LNCaPs than c4–2b cells (P = 0.0029), whilst
the reduction in expression levels of TYMS and SKP2 was
greater in c4–2b than LNCaP cells (P = 0.00031 and P
= 0.0010, respectively), suggesting that additional cell cy-
cle regulatory mechanisms could be present in AI PC cells.
Higher levels of CDK4 and cyclin D1, which are responsi-
ble for G1/S-phase progression (75) were also observed in
the GABP KD cells (Supplementary Figure S4D), which
could be a response to higher levels of p27Kip1 (76). The
stimulation of cell growth and proliferation by GABP in
PC cells may also reflect the regulation of metabolic gene
signatures for central metabolism, mitochondrial function
and steroid biogenesis, which would cooperate with cell cy-
cle targets of GABP to fuel PC cell growth. Previous re-
ports have also implicated GABP in mitochondrial bio-
genesis in other tissues (77,78), providing a wider context
for the results of our genomics studies in PC and under-
scoring the potential importance of the metabolic targets of
GABP in PC.
Analysis of differentially expressed genes in GABP PC
cells suggested that GABP exerts its effects through dif-
ferent pathways in AD and AI PC. This is supported by the
recent findings thatGABP is critical for the both themain-
tenance and differentiation of haematopoietic stem cells
through its regulation of FOXO3, PTEN and p300 (79) and
that it is essential for the self-renewal of embryonic stem
cells through regulation ofOct-3/4 expression (17). GABP
is itself a target of STAT3 (17), a signalling pathway im-
plicated in the development and progression of PC (80).
GABP could be one of the critical regulators of differen-
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tiation of PC stem cells, which are known to be associated
with PC progression and metastasis.
The transcriptional activity of GABP has been well
characterized in myeloid cells where it regulates lineage-
restricted genes through interactions with other transcrip-
tion factors (81,82). It has also been shown to modulate
hormone responsiveness to retinoids in myeloid cells (9),
raising the possibility that GABP could mediate the hor-
mone responsiveness of AR target genes in PC through sim-
ilarmechanisms. The convergence ofARandGABP at the
target gene binding and gene regulation levels, together with
their differing genomic binding profiles, raise the hypothesis
that GABP promoter occupancy may impinge on chro-
matin looping of distal AR-binding sites to target genes,
although detailed future biochemical and functional stud-
ies will be required to determine the precise mechanisms at
play. GABP can also be activated by MAPK phosphory-
lation, implicating it as a modulator of AR target gene se-
lection and/or in ligand-independent roles of the AR. The
identification of a subset of genes with differential expres-
sion in GABP OE PC cells and AR genomic occupancy
but which are not androgen-regulated in vitro implicates
GABP in the in vivoAR transcriptional programme which
we have previously observed in CRPC tissue (Figures 2D
and 3G–I). To test this hypothesis future studies will also
need to focus on mapping GABP binding in CRPC tissue.
Our study highlights increased expression ofGABP and
its regulation of key transcriptional pathways in PC, how-
ever the mechanisms upstream of GABP will require fur-
ther investigation. Preliminary analyses of the signals which
regulate GABP expression and activity highlight a com-
plex network upstream of GABP both at the transcript
and protein level, including many pathways known to be
altered in PC (Supplementary Figure S5). Specifically, we
found: (1) convergence of ETS, forkhead, NFKB, MYC,
SP1, YY1 and ATF2 transcription factors on the GABP
promoter in several cell types; (2) evidence of transcrip-
tional regulation of the GABP gene by ATF2, SOCS3 and
TGF; (3) regulation of GABP protein activity by NRG1
cascades involving RAF/MEK/ERK and JNK signalling;
(4) regulation of GABP by PGC-1a, implicating altered
metabolism and/or diet in the regulation of GABP; (5)
11 curated protein interaction partners of GABP which
include five known AR interaction partners (SP1, MED1,
EP300, CREBP, HDAC1). Future in-depth investigations
will be required to dissect the relative contribution of each
of these signalling pathways to the up-regulation ofGABP
expression and activity in PC and CRPC. However, the
strong convergence of GABP and AR protein interactions
lends further support to a functional convergence of these
two transcription factors.
In conclusion, the ETS family member GABP interacts
with the AR and plays a critical role in PC, mediating a
malignant phenotype in AR positive PC cells. GABP tar-
gets are overexpressed in metastatic PC and are predictive
of survival in PC clinical expression data sets, supporting a
critical and potentially clinically relevant role for GABP
in CRPC. GABP has a transcriptional role in PC that is
distinct from that of the ETS family member ERG that is
commonly rearranged in PC, but shows striking similari-
ties to another ETS family member commonly rearranged
in PC, ETV1. These divergent sets of transcriptional targets
are surprising given the high proportion of AR-ERG, AR-
ETV1 and ERG-ETV1 overlapping binding sites (Figure
2C and Supplementary Figure S2), but are consistent with
several recent reports which suggest that ERG and ETV1
gene fusions exert their pro-tumourigenic effects through
divergent pathways (24–26). Our study therefore adds fur-
ther resolution to identify the critical transcriptional net-
works that mediate the malignant phenotype in PC and fur-
ther highlights the importance of ETS genes beyond those
involved in common gene fusions in PC.
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